Molecular profiling of NSCLC has identified genomic subsets of NSCLC such as EGFR mutant NSCLC and KRAS mutant NSCLC with co-occurring mutations in the Nrf2 axis (STK11, KEAP1, and NFE2L2) that appear resistant to CPI monotherapy [1-3]. Here, STK11 is linked to non-small cell lung carcinoma.